Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
Submitted by
admin
on May 22, 2018 - 9:53am
Source:
CP Wire
News Tags:
CytomX
AbbVie
CX-2029
cancer
Headline:
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
snippet:
Co-developing drug with Abbvie
CytomX is eligible to receive up to $470 million in development, regulatory and commercial milestones
CD71 highly expressed protein present in a number of solid and hematologic cancers
Additional collaboration agreements with Abbvie, Bristol-Myers Squibb, ImmunoGen
Do Not Allow Advertisers to Use My Personal information
